Posted by Defense World Staff on Aug 19th, 2024
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT – Get Free Report) saw a significant growth in short interest in July. As of July 31st, there was short interest totalling 4,230,000 shares, a growth of 7.4% from the July 15th total of 3,940,000 shares. Based on an average trading volume of 421,200 shares, the short-interest ratio is currently 10.0 days. Currently, 13.9% of the shares of the company are short sold.
Wall Street Analyst Weigh In
Separately, HC Wainwright decreased their target price on shares of Checkpoint Therapeutics from $34.00 to $20.00 and set a “buy” rating for the company in a research note on Monday, August 12th.
Read Our Latest Stock Analysis on CKPT
Checkpoint Therapeutics Stock Performance
Shares of CKPT stock remained flat at $2.21 during mid-day trading on Monday. 38,739 shares of the stock traded hands, compared to its average volume of 467,086. The firm has a market cap of $78.87 million, a price-to-earnings ratio of -0.80 and a beta of 1.25. The company has a fifty day simple moving average of $2.24 and a 200-day simple moving average of $1.99. Checkpoint Therapeutics has a one year low of $1.30 and a one year high of $3.62.
Insider Buying and Selling at Checkpoint Therapeutics
In other news, CFO William Garrett Gray sold 13,038 shares of Checkpoint Therapeutics stock in a transaction dated Wednesday, June 26th. The stock was sold at an average price of $2.06, for a total transaction of $26,858.28. Following the sale, the chief financial officer now owns 672,186 shares in the company, valued at $1,384,703.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CEO James F. Oliviero III sold 24,610 shares of the company’s stock in a transaction on Wednesday, June 26th. The shares were sold at an average price of $2.05, for a total value of $50,450.50. Following the completion of the sale, the chief executive officer now owns 1,977,170 shares in the company, valued at approximately $4,053,198.50. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO William Garrett Gray sold 13,038 shares of the stock in a transaction on Wednesday, June 26th. The stock was sold at an average price of $2.06, for a total transaction of $26,858.28. Following the sale, the chief financial officer now owns 672,186 shares of the company’s stock, valued at approximately $1,384,703.16. The disclosure for this sale can be found here. 2.10% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
Several large investors have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC lifted its holdings in Checkpoint Therapeutics by 92.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 11,174 shares of the company’s stock valued at $26,000 after acquiring an additional 5,375 shares during the period. XTX Topco Ltd acquired a new stake in shares of Checkpoint Therapeutics in the second quarter valued at about $34,000. Choreo LLC purchased a new stake in Checkpoint Therapeutics during the fourth quarter worth about $44,000. Magnus Financial Group LLC acquired a new position in Checkpoint Therapeutics during the fourth quarter worth about $55,000. Finally, Lindbrook Capital LLC purchased a new position in Checkpoint Therapeutics in the first quarter valued at about $62,000. 22.00% of the stock is owned by hedge funds and other institutional investors.
About Checkpoint Therapeutics
Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.
See Also
- Five stocks we like better than Checkpoint Therapeutics
- What Are Dividends? Buy the Best Dividend Stocks
- JD.com’s Record Net Profit Underscores Its Financial Strength
- Most Volatile Stocks, What Investors Need to Know
- Berkshire Hathaway’s Latest Portfolio Moves: A Strategic Shuffle
- How to Use the MarketBeat Stock Screener
- 3 Affordable Stocks Under $10 Ready to Rebound Soon
Receive News & Ratings for Checkpoint Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkpoint Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
You might be interested in:
CLPS Incorporation Short Interest Update
Checkpoint Therapeutics, Inc. Short Interest Update
Short Interest in Global X Cloud Computing ETF Drops By 12.0%
ChampionX Co. Sees Significant Increase in Short Interest
Short Interest in Clean Energy Fuels Corp. Decreases By 8.9%
